Ursprung des Netzwerks ersten Grades von Simon Meier
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Roche Ventures
Roche Ventures Investment ManagersFinance Roche Ventures is the venture investment division of the pharmaceutical company F. Hoffmann-La Roche Ltd., which is a subsidiary of Roche Holding AG (SWX:ROG). The group is headquartered in Basel with operations and affiliates worldwide, and is a world leader in pharmaceuticals and diagnostics. The firm was founded in 2002.
10
| Subsidiary | Investment Managers | 10 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Simon Meier
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Millendo Therapeutics US, Inc.
Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
ALLAKOS INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
ROCHE HOLDING AG | Pharmaceuticals: Major | Director of Finance/CFO Investor Relations Contact | |
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
Rempex Pharmaceuticals, Inc.
Rempex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
PanOptica, Inc.
PanOptica, Inc. Pharmaceuticals: MajorHealth Technology PanOptica, Inc. operates as a biopharmaceutical company that provides ophthalmology drugs for treatment of eye diseases. The company was founded by Paul G. Chaney and Martin B. Wax in March 2009 and is headquartered in Bernardsville, NJ. | Pharmaceuticals: Major | Director/Board Member | |
Bonum Therapeutics, Inc.
Bonum Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bonum Therapeutics, Inc. is a privately held American company that focuses on generating a new class of therapeutics based on a proven technology platform. Bonum Therapeutics is based in an undisclosed location and was founded in 2022 by the Good Therapeutics team. The company's technology utilizes principles of allosteric regulation to create highly active and less toxic medicines, which can be applied to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. The company's molecules combine a sensor component directed against a specific biological marker and a therapeutic component. The company is backed by a group of leading venture investors, including Codon Capital, Roche Venture Fund, RiverVest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital. The company was founded by John Mulligan, who has been the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
Good Therapeutics, Inc.
Good Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Good Therapeutics, Inc. operates as a biotechnology company. It develops "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. The company was founded by John Mulligan in 2016 and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Director/Board Member | |
GlycoEra AG
GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | Biotechnology | Director/Board Member | |
Lino Biotech AG
Lino Biotech AG Miscellaneous Commercial ServicesCommercial Services Lino Biotech AG provides foal molography technology. It is a novel label-free biosensor platform for direct imaging of biomolecular interactions in living cells. The company was founded by Mirko Stange, Volker Gatterdam, and Andreas Fruter and is headquartered in Zurich, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
MacuLogix, Inc.
MacuLogix, Inc. Medical/Nursing ServicesHealth Services MacuLogix, Inc. engages in the early detection and tracking of retinal diseases. Its AdaptDx is the first practical measurement tool for dark adaptation which provides doctors with an easy-to-use functional test similar to routine perimetry testing for glaucoma. The company also provides macular degeneration services. The company was founded by John G. Edwards and Gregory R. Jackson in 2004 and is headquartered in Harrisburg, PA. | Medical/Nursing Services | Director/Board Member | |
CiVi Biopharma Holdings, Inc.
CiVi Biopharma Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services CiVi Biopharma Holdings, Inc. operates as a clinical stage research and development biotechnology company. It create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company is headquartered in Bryn Mawr, PA. | Miscellaneous Commercial Services | Director/Board Member | |
ENTRADA THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
University of San Francisco | College/University | Masters Business Admin | |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member | |
Zikani Therapeutics, Inc.
Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA. | Drugstore Chains | Director/Board Member | |
BioMedPartners AG
BioMedPartners AG Investment ManagersFinance BioMedPartners AG (BMP), is an independant venture capital firm headquartered in Basel, Switzerland. BMP originated in 2002 as Seed Capital Advisors AG. The firm manages sector-focused venture capital funds including BioMedInvest, BioMedInvest II and BioMedCredit. They specialize in the biomedical sector. | Investment Managers | Private Equity Investor | |
Enthera Srl
Enthera Srl BiotechnologyHealth Technology Enthera Srl develops therapeutic solutions to treat diabetes. The company was founded in 1985 by in October 2016 by Maria Gabriella Camboni, Paolo Fiorina and Francesca D'Addio and is headquartered in Milan, Italy. | Biotechnology | Director/Board Member | |
University of Zurich | College/University | Graduate Degree | |
AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Lengo Therapeutics, Inc.
Lengo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lengo Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Menlo Park, CA. | Pharmaceuticals: Major | Chief Executive Officer | |
Instituto de Empresa SL | College/University | Masters Business Admin | |
The University of Sydney | College/University | Doctorate Degree | |
Seventure Partners SA
Seventure Partners SA Investment ManagersFinance Seventure Partners SA (Seventure) is a Venture Capital firm, a subsidiary of Natixis SA founded in 1997. Seventure Partners SA is headquartered in Paris. | Investment Managers | Private Equity Investor | |
Soteria Biotherapeutics, Inc.
Soteria Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Soteria Biotherapeutics, Inc. develops next-generation immunotherapies. Its development allows to control the activity of immunomodulatory therapeutics such as bi-specific T-cell engagers (BiTEs) and CAR T-cells.The company was founded by Zachary Hill and Alexander Martinko and is headquartered in San Francisco, CA. | Pharmaceuticals: Major | Director/Board Member | |
Purigen Biosystems, Inc.
Purigen Biosystems, Inc. BiotechnologyHealth Technology Purigen Biosystems, Inc. engages in extracting, enriching and quantifying DNA and RNA from biological samples. The company was founded in 2012 by Amy Hiddessen, Klint Rose and Juan Santiago and is headquartered in Pleasanton, CA. | Biotechnology | Director/Board Member | |
Columbia University College of Physicians & Surgeons | College/University | Doctorate Degree | |
Epic Sciences, Inc.
Epic Sciences, Inc. Medical SpecialtiesHealth Technology Epic Sciences, Inc. develops novel diagnostics to the treatment and management of cancer. It develops sensitive diagnostic tests to molecularly characterize circulating tumor cells in the blood. The firm also offers fluid-phase biopsy that identifies rare cell of interest in the blood; and provides cancer management through earlier diagnosis, staging and therapeutic selections. The company was founded by David M. Nelson in 2008 and is headquartered in San Diego, CA. | Medical Specialties | Director/Board Member | |
Dolby Family Ventures LLC
Dolby Family Ventures LLC Investment ManagersFinance Dolby Family Ventures (Dolby) is a venture capital firm founded in 2013. The firm is headquartered in San Francisco, California. | Investment Managers | Private Equity Investor | |
Aucupo Biosciences, Inc.
Aucupo Biosciences, Inc. BiotechnologyHealth Technology Aucupo Biosciences, Inc. is engaged in biotechnology services. The company was founded by Tracy Saxton and is headquartered in Seattle, WA. | Biotechnology | Chief Executive Officer | |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member | |
Pivotal Bioventure Partners Investment Advisor LLC
Pivotal Bioventure Partners Investment Advisor LLC Investment ManagersFinance Pivotal Bioventure Partners Investment Advisor LLC (Pivotal Bioventure) is a venture capital firm founded in 2017 by Vincent Cheung. The firm is headquartered in San Francisco, California. | Investment Managers | Private Equity Investor | |
VAXCYTE, INC. | Biotechnology | Director/Board Member | |
The Damon Runyon Cancer Research Foundation
The Damon Runyon Cancer Research Foundation Miscellaneous Commercial ServicesCommercial Services The Damon Runyon Cancer Research Foundation supports cancer research through grants to scientists in fields including cellular biology, genetics, immunology, and virology. It was founded in 1946 and is headquartered in New York City, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Simon Fraser University | College/University | Undergraduate Degree | |
The Trustees of Columbia University in The City of New York | College/University | Masters Business Admin | |
University of Toronto | College/University | Doctorate Degree | |
GERON CORPORATION | Biotechnology | Corporate Officer/Principal | |
Roche Venture Fund
Roche Venture Fund Investment ManagersFinance Roche Venture Fund seeks investments in innovative technology oriented companies with the focus on biotechnology and medicine. | Investment Managers | Corporate Officer/Principal | |
ALIGOS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
EngMab SARL
EngMab SARL Pharmaceuticals: MajorHealth Technology EngMab SARL operates as a biotechnology company. It focuses on cancer immunotherapy and hematological malignancies and solid tumors. The company was founded by Klaus Strein in 2013 and is headquartered in Pfäffikon, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Lamkap Bio Alpha AG | Chairman | ||
Discoveric AG | Chairman |
Statistik
International
Vereinigte Staaten | 33 |
Schweiz | 9 |
Spanien | 3 |
Kanada | 3 |
Vereinigtes Königreich | 2 |
Sektoral
Health Technology | 28 |
Consumer Services | 9 |
Finance | 7 |
Commercial Services | 6 |
Health Services | 2 |
Operativ
Director/Board Member | 47 |
Private Equity Investor | 13 |
Chairman | 13 |
Corporate Officer/Principal | 11 |
Director of Finance/CFO | 6 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Simon Meier
- Unternehmensverbindungen